No retraction, correction or concern found when last checked on Oct 17, 2026.
Therapeutic application of quercetin in aging-related diseases: SIRT1 as a potential mechanism
Zhifu Cui, Xingtao Zhao, Felix Kwame Amevor and 6 more
Frontiers in Immunology · 2022 · Review · CC BY
Abstract
Quercetin, a naturally non-toxic flavonoid within the safe dose range with antioxidant, anti-apoptotic and anti-inflammatory properties, plays an important role in the treatment of aging-related diseases. Sirtuin 1 (SIRT1), a member of NAD + -dependent deacetylase enzyme family, is extensively explored as a potential therapeutic target for attenuating aging-induced disorders. SIRT1 possess beneficial effects against aging-related diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), Depression, Osteoporosis, Myocardial ischemia (M/I) and reperfusion (MI/R), Atherosclerosis (AS), and Diabetes. Previous studies have reported that aging increases tissue susceptibility, whereas, SIRT1 regulates cellular senescence and multiple aging-related cellular processes, including SIRT1/Keap1/Nrf2/HO-1 and SIRTI/PI3K/Akt/GSK-3β mediated oxidative stress, SIRT1/NF-κB and SIRT1/NLRP3 regulated inflammatory response, SIRT1/PGC1α/eIF2α/ATF4/CHOP and SIRT1/PKD1/CREB controlled phosphorylation, SIRT1-PINK1-Parkin mediated mitochondrial damage, SIRT1/FoxO mediated autophagy, and SIRT1/FoxG1/CREB/BDNF/Trkβ-catenin mediated neuroprotective effects. In this review, we summarized the role of SIRT1 in the improvement of the attenuation effect of quercetin on aging-related diseases and the relationship between relevant signaling pathways regulated by SIRT1. Moreover, the functional regulation of quercetin in aging-related markers such as oxidative stress, inflammatory response, mitochondrial function, autophagy and apoptosis through SIRT1 was discussed. Finally, the prospects of an extracellular vesicles (EVs) as quercetin loading and delivery, and SIRT1-mediated EVs as signal carriers for treating aging-related diseases, as well as discussed the ferroptosis alleviation effects of quercetin to protect against aging-related disease via activating SIRT1. Generally, SIRT1 may serve as a promising therapeutic target in the treatment of aging-related diseases via inhibiting oxidative stress, reducing inflammatory responses, and restoring mitochondrial dysfunction.
Full text
From PubMed Central, U.S. National Library of Medicine, as current on Oct 17, 2026. Paragraph numbers are ours, so an answer can point at one.
Highlights:
1. Quercetin, a naturally non-toxic flavonoid within the safe dose range with antioxidant, anti-apoptotic, and anti-inflammatory properties, plays an important role in the treatment of aging-related diseases.
2. Quercetin exerts neuroprotective effects against chronic aging-related diseases via targeting SIRT1 to regulate cellular senescence and multiple aging-related cellular processes such as SIRT1/Keap1/Nrf2/HO-1 and PI3K/Akt/GSK-3β mediated oxidative stress, SIRT1/NF-κB mediated inflammatory response, SIRT1/PGC1α/eIF2α/ATF4/CHOP mediated mitochondrial damage, and SIRT1/FoxO mediated autophagy.
3. Studies on the preventive and therapeutic effects and clinical application of natural SIRT1 activator or synthetic SIRT1 activator on aging-related diseases could provide a strong foundation and basis for investigating further potential target drugs to attenuate aging-related diseases.
1 Introduction
Aging in both animals and humans is positively correlated with a decline in the physiological functions, thereby increasing the occurrence of aging-related diseases; such as neurodegenerative diseases (NDS) including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and Depression; as well as other related diseases such as Osteoporosis, Myocardial ischemia (M/I) and reperfusion (MI/R), Atherosclerosis (AS), and Diabetes. A study reported that aging-related NDS caused significant morbidity and economic burden of approximately $25 billion annually in the USA. Therefore, several researchers engaged in studies to explore the molecular mechanism of various aging related diseases.
Chronological aging cause subtle changes in the neuronal structure and function of specific neuronal circuits, resulting in significant decrease in dopamine receptors in the striatum and reactive microglia and astrocytes, and the overactivation of proinflammatory microglia which triggers chronic inflammation. The production and accumulation of free radicals causes oxidative stress which increases the production of proinflammatory cytokines, leading to neuronal cell death and glial cell activation. However, Sirtuin 1 (SIRT1) regulates the expression of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin-1 β (IL-1β), and interferon γ (IFN-γ) during microglial activation, as well as alleviates degeneration of dopaminergic neurons.
Sirtuin (SIRT), a member of the NAD+-dependent deacetylase enzyme family, regulates various cellular targets and functions. SIRT1 is the most widely studied Sirtuin in mammals and is considered as a potential therapeutic target for aging-associated disorders. SIRT1 activation was reported to attenuate other age-associated disorders such as NDS. Several aging-related markers such as neuroinflammation, oxidative stress, activation of glial cell, inhibition of adaptive neuroplasticity, dysregulation of neuronal Ca2+ homeostasis, mitochondrial dysfunction, and cellular senescence elevate the risk of aging-related diseases. Studies have indicated that SIRT1 silencing intensify the formation of aging-related inclusions containing alpha-synuclein, increase the number of age-dependent degeneration of dopaminergic neurons, which intensify the progression of related diseases. Moreover, excessive production of free radicals causes cell damage, leading to oxidative and nitrosative stress, which disrupts the immune function and hence, induces series of aging-related diseases. SIRT1 modulates the production and accumulation of reactive oxygen species (ROS) in vitro and in vivo, thereby attenuating oxidative stress associated with neurodegeneration.
ROS accumulation cause mitochondrial dysfunction and cell death due to excessive inflammation, this allows the development of aging-related diseases. However, SIRT1 promotes mitochondrial function and regulates mitochondrial homeostasis. Studies have indicated that overexpression of SIRT1 can effectively inhibit cell death, promote cell survival, and prolong the lifespan of cells. However, available strategies such as chemical drugs to treat diseases are very expensive, less clinically effective, and have obvious toxic effects. Therefore, researchers are currently studying to develop potent, cheap, safe, and more effective natural alternatives or novel targets to attenuate aging-induced diseases.
Quercetin (2-(3,4-dihydroxy phenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one) (Figure 1) is one of the major naturally nontoxic flavonoids which is widely found in fruits (grapes, peaches) and vegetables (onions, garlic). Quercetin is a lipophilic compound that could be absorbed by simple diffusion across the intestinal membrane, however, it is ingested primarily as a glycoside, which is converted to a glycoside ligand in the intestine, and then release by absorption into the intestinal epithelium through the action of β-glycosidase, and both the intestinal and oral bacteria are involved in this enzymatic hydrolysis. Studies have shown that poor oral bioavailability of single doses. The poor aqueous solubility of quercetin (~1 mg/mL in water, ~5.5 mg/mL in simulated gastric fluid, and ~28.9 mg/mL in simulated intestinal fluid) and its instability in the physiological media have limited its application in pharmacology, great efforts have been made in its drug delivery systems to address the problem of limited application.
Quercetin plays many beneficial roles such as antioxidant, anti-inflammatory, anti-apoptotic and other biological activities in neuroprotection. Reports have indicated that quercetin contain anti-aging properties. However, the mechanisms through which quercetin exert these functions are complex and the signaling pathways are intertwined. Therefore, our aim in this review was to clarify how quercetin targets SIRT1 to prevent aging-related diseases, elucidate the relationships between the relevant signaling pathways, provide the possible targets and the theoretical basis for quercetin to serve as an effective drug for aging-related diseases.
2.1 Alzheimer’s disease (AD)
Alzheimer’s disease (AD) is a neurodegenerative disorder, characterized by learning and memory dysfunction at an early stage and eventually evolves into a cognitive disorder. Due to the progression of the disease and limited treatment options, AD has become one of the greatest threats to the modern population, accounting for approximately 45 million patients worldwide. Studies have predicted that by the year 2050, approximately 150 million people may suffer from AD.
The mechanisms of AD are related to the deposition of β-amyloid (Aβ) peptides and intracellular neurofibrillary tangles consisting of hyperphosphorylated tau protein, which are important characteristics of AD and can lead to serial neuronal loss and brain atrophy. SIRT1 regulates the expression of Aβ and tau, which are associated with AD. A study using a three-transgenic AD (3XTG-AD) mice model, reported that quercetin (100 mg/kg) significantly improved the biomarkers of neurodegeneration and cognitive and emotional deficits.
2.1.1 Regulation of oxidative stress
In addition to its direct toxic effects on neurons, Aβ increases the sensitivity of neurons to harmful factors such as free radicals and oxidative stress, which play important role during AD. Quercetin supplementation reduce microglia aggregation around amyloid plaques in AD mice through various excess protein pathways. Activation of SIRT1 was reported to counteract oxidative stress induced by Aβ aggregation. In addition, Yu et al. reported that quercetin regulates SIRT1/Nrf2/HO-1 pathway thereby exerting neuroprotective effects against AD. In HT22 hippocampal neurons, quercetin was reported to show a neuroprotective effect by promoting phosphoinositide 3-kinase (PI3K)/Akt which could downregulate glycogen synthase kinase 3beta (GSK-3β) activity, thereby reducing oxidative stress-mediated neuronal death.
2.1.2 Regulation of inflammatory response
Aβ promotes the activation of microglia and the release of inflammatory cytokines. Chronic inflammation is associated with age-related Alzheimer’s disease. Studies have shown that quercetin exerts an anti-neuroinflammatory effects on LPS-activated BV-2 microglial cells, by attenuating the production of inflammatory mediators, including nitric oxide (NO) and TNF, as well as reduce the level of inducible NO synthase (iNOS). Quercetin reduces ROS production by promoting the activity of SIRT1 and enhancing the anti-inflammatory activity of NF-κB acetylation in the neural and glial cells, thereby reducing neuronal cell death.
2.1.3 Regulation of mitochondrial function
Mitochondria are organelles responsible for ATP production, calcium regulation, and regulation of redox homeostasis. Mitochondrial dysfunction is regarded as the main causative factor of the pathogenesis aging-related AD, as a result could inflict damage to neurons, microglia, and astrocytes. Microglia phagocytose Aβ and the surrounding Aβ plaques promote the synaptic and neuronal loss in the chronic AD process in the mitochondrial dysfunction and hence, increase LAMP1 immunoreactivity, thereby preventing the diffusion of soluble amyloid into the surrounding thin-walled brain. In addition, quercetin was found to improve the cognitive function in the APPswe/PS1De9 transgenic mice model during chronic AD, by reducing mitochondrial dysfunction via the activation of AMP-activated protein kinase (AMPK). Moreover, SIRT1 regulates mitochondrial biogenesis and function by directly controlling the activity of proliferator-activated receptor gamma coactivator 1alpha (PGC-1α) through phosphorylation and deacetylation, whereas quercetin cause a reduction in the phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2α), as well as activate the expression of transcription factor 4 (ATF4) through the GADD34 induction in the brain, leading to memory improvement in aged mice and delayed memory deterioration at the early stage of APP23 AD model mice.
2.1.4 Regulation of autophagy function
Autophagy is the main mechanism underlying the onset and progression of AD. FoxO proteins, key substrates of SIRT1, are prominent and necessary factors in the formation of memory and cognitive function. Studies in a drosophila AD model have shown that quercetin significantly alleviate chronic AD by restoring the expression of cell cycle protein including cell cycle proteins B located in the FoxO signaling pathway perturbed by Aβ accumulation.
In summary, quercetin exerts neuroprotective effects against chronic AD by targeting SIRT1 to regulate cellular senescence and aging-related multiple cellular processes, including SIRT1/Keap1/Nrf2/HO-1 and PI3K/Akt/GSK-3β mediated oxidative stress, SIRT1/NF-κB mediated inflammatory response, SIRT1/PGC1α/eIF2α/ATF4/CHOP mediated mitochondrial damage, and SIRT1/FoxO mediated autophagy (Figure 2 and Table 1).
2.2 Parkinson’s disease (PD)
Parkinson’s disease (PD) is a common progressive neurodegenerative disease after AD, which affects approximately 1-2% of people at the age ≥ 65. PD is characterized by dopaminergic (DAergic) neuronal deficits and glial dysfunction in the substantia nigra (SN), caused by neuroglial dysfunction and neuroinflammation. Studies have shown that α-synuclein (α-SYN) regulates pathological events that cascade the response in PD, whereas SIRT1 proteins modulates PD.
2.2.1 Regulation of oxidative stress
Oxidative stress is a major inducers of PD pathogenesis. This is because ROS activates α-syn aggregation cascade, together with Lewy bodies, promotes neurodegeneration. In a 6-hydroxydopamine (6-OHDA) PD rat model, it was observed that quercetin alleviated the unilateral medial forebrain tract (annigra lesion) or the striatum (part lesion) through the antioxidant, anti-inflammatory, and protective neurotransmitter mechanisms. The efficacy of quercetin was tested in MitoPark transgenic chronic PD mice model, to ameliorate striatal dopamine depletion and 5-TH neuronal cell loss. Other studies have shown that different doses of quercetin reduce oxidative damage by regulating SIRT1/HO-1/Nrf2 pathway, thereby increasing neuronal density. Furthermore, Nrf2 modulates ARE/PINK1 expression, to restore mitochondrial homeostasis in chronic PD.
2.2.2 Regulation of inflammatory response
PD activates microglia to promote inflammatory processes by releasing inflammatory cytokines and chemokines. Moreover, degeneration of dopaminergic neurons is induced by the synergy of ROS, neuroinflammation, and loss of other trophic factors. In the microglial (N9)-neuronal (PC12) co-culture systems, quercetin downregulates the expression of proinflammatory cytokines in the N9 microglia, and reduce apoptosis in the post-neuronal cells. Studies have reported that quercetin alleviates manganese-induced neuroinflammation by inhibiting apoptosis and oxidative stress through the SIRT1/iNOS/NF-κB and HO-1/Nrf2 pathways. NLRP3 inflammatory vesicle is one the most characterized inflammatory vesicles, which can be activated by highly diverse stimuli. NLRP3 is activated by procaspase-1, which in turn induces maturation and secretion of inflammatory cytokines, as well as plays an important role in PD. Studies have shown that quercetin impedes microglial activation by inhibiting the interaction between the NLRP3 inflammasome and mitochondrial autophagy to reduce neurotoxicity. In aged mice, quercetin was reported to attenuate neuroinflammation by modulating the SIRT1/NLRP3 pathway.
2.2.3 Regulation of mitochondrial function
Excessive ROS production and accumulation cause mitochondrial dysfunction by α-SYN, which subsequently results in neurodegeneration. However, quercetin is significantly induced in MN9D dopaminergic neuronal cells, two major cell survival kinases, and the activation of PD protein kinase D1 (PKD1) and Akt. The cAMP response element-binding protein (CREB) and a transcriptional activator of brain-derived neurotrophic factor (BDNF), are involved in microglial activation. Interestingly, quercetin (10 μM) was found to upregulate BDNF gene expression in the dopaminergic neuronal cells through phosphorylating CREB by PKD1 or through stimulating mitochondrial biology in the dopaminergic neuronal cells via regulating SIRT1/PGC-1α transcriptional activity through CREB generation. Moreover, mitochondria act as a key regulator for NLRP3 inflammatory vesicles, whereas mitochondrial dysfunction leads to NLRP3 assembly and activation. Mitochondrial dysfunction in the astrocytes amplifies the activity of the NLRP3 inflammasome, as well as promotes IL-1β production.
2.2.4 Regulation of autophagy function
α-SYN regulates autophagosome synthesis, leading to defective autophagy. Quercetin acts as an autophagy enhancer in aged PD rat models and modulate the microenvironment leading to neuronal death. PTEN is responsible for inducing putative kinase 1 (PINK1) that contributes to the development of astrocyte and proliferation, as well as was identify as an essential protein for the removal of the damaged mitochondria via autophagy. PINK1-parkin-mediated dysfunction of the mitochondrial autophagy in the astrocytes can impair the integrity of the mitochondria, which leads neuronal dysfunction and degeneration. Reports have shown that quercetin activates SIRT1, promotes autophagic PINK1 activation, and reduces cytochrome c release, as well as enable cystatinase activation to maintain mitochondrial integrity, thereby preventing apoptosis. Quercetin regulates the protein expression of Bcl2/Bax and the release of cytochrome c, and nuclear translocation of apoptosis-inducing factor (AIF). Quercetin also promotes autophagy and modulates the microenvironment which leads to neuronal death.
Therefore, quercetin is a potential therapeutic strategy for alleviating PD by targeting SIRT1. Developing therapies have shown that SIRT1/Nrf2/HO-1 mediated oxidative stress, SIRT1/NF-κB/NLRP3 pathway ameliorates neuroinflammation SIRT1-mediated PKD1/CREB phosphorylation and BDNF gene expression, and regulates mitochondrial disorders in the dopaminergic neurons and SIRT1-PINK1-Parkin mediated mitochondrial autophagy in the astrocytes to maintain mitochondrial function (Figure 3 and Table 2).
2.3 Effects of quercetin on Huntington’s disease (HD)
Huntington’s disease (HD) is a neurodegenerative disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra, as well as progressive motor dysfunction, chorea, dystonia, mood disturbances, memory, and weight loss. Symptoms of HD in humans usually appear between the ages 30-50 years and increase in severity with chronological age. Current disease palliative therapies for HD focus on reducing the levels of mutant huntingtin (mHTT) in brain cells. The overexpression of SIRT1 was reported to increase the survival in R6/2 HD mice and improve neuropathology and reduced mHTT aggregation in R6/2 models.
2.3.1 Regulation of mitochondrial function
In 3-nitropropionic acid (3-NP)-induced HD rat models, quercetin maintain mitochondrial function by attenuating oxidative stress and neurobehavioral disorder. In addition, dysfunction of mitochondrial metabolism of mHTT play major role in the pathogenesis of HD which is primarily associated with impair respiratory chain function, thereby increasing ROS production and subsequently results in cell death. Furthermore, the ubiquitin-proteasome system (UPS) or autophagy reduce the formation of toxic mHTT aggregates. A study showed that inducement of mHTT could decrease the proteasomal activity of UPS which could be reverse by the quercetin (20 µM), thereby attenuating mitochondrial membrane potential damage.
2.3.2 Regulation of inflammatory response
It was established that quercetin could alleviate HD in rat model by regulating inflammatory changes (IL-1β, IL-6, and TNF) associated with growth factors released from astrocytes by the reduction of microglial proliferation, as well as increasing astrocyte numbers. In addition, quercetin reduce anxiety and depression in patients with 3-NP-induced chronic HD. This indicate that quercetin plays neuroprotective role in HD by targeting SIRT1 to relieve mHTT aggregation in patients, and restore mitochondrial function and reduce inflammation (Figure 4 and Table 3).
2.4 Effects of quercetin on depression
Major depressive disorder may be associated with volumetric indications of accelerated brain aging. Disorders of depression and anxiety are common mental ailments that imposes a significant global health challenge. However, current conventional antidepressants have limited efficacy, significant side effects and expensive. The structural and functional integrity of the hippocampus is critical for cognitive functions, as well as producing antidepressant effects in response to adverse factors (environmental changes, stress). Moreover, reports have indicated that SIRT1 inhibitors reverse sleep deprivation (SD)-induced depressive and anxiety-like behaviors and hippocampal neuroinflammation. The role and possible mechanisms of SIRT1 have revealed novel therapeutic strategies for clinical treatment of depression. SIRT1 is required for normal neuronal excitability and regulates depression-related behaviors in a sex-specific manner. Activation of the estrogen receptor alpha (ERα)/SIRT1/NF-κB pathway was involved in LPS-induced depression in aged female mice.
Fork head box transcription factor G1 (FOXG1) play neuroprotective roles by regulating adult hippocampal neurogenesis (AHN). Quercetin promotes AHN via FoxG1/CREB/BDNF signaling pathway to improve chronic unpredictable mild stress (CUMS)-induced depression-like behaviors. In addition, it has been shown that microglial inhibitory pathways exert neuroprotective effects, and astrocyte activation, whereas quercetin significantly reduce the frequency of spontaneous excitatory postsynaptic currents (sEPSCs) and spontaneous inhibitory postsynaptic currents (sIPSCs) to antidepressants. Astrocytes secrete neurotrophic factors such as GDNF and BDNF, of which BDNF combined with exercise training attenuated 1,2-dimethylhydrazine-induced depression in rats with colorectal cancer by modulating the BDNF/tyrosine receptor kinase A (TrKβ)/β-catenin axis in the prefrontal cortex significantly reduced tumorigenesis and improve depression-like behavior, as well as attenuates LPS-induced depression-like behavior in rats by modulating the BDNF-related Copine 6 and TREM1/2 imbalance in the hippocampus and PFC, whereas reports showed that quercetin exert antidepressant and cardioprotective effects.
Quercetin reduce doxorubicin-induced anxiety by enhancing immune function and reducing oxidative stress in the brain. Alteration in the metabolism of monoamine oxidase (MAO) is associated with aging, which catalyzes monoamine-containing neurotransmitters such as serotonin 5-hydroxytryptamine (5-HT). Quercetin possess antidepressant-like effects through its antioxidant, anti-inflammatory activities, and also reduce excitotoxicity, as well as increase 5-HT levels. Quercetin significantly reduced MAOs activity and increase the activity of antioxidant enzymes (Cu-Zn, SOD, CAT, and GSH-Px) in depressed rats. Some studies in olfactory bulbectomy (OB), the surgical removal of the olfactory bulbs, cause specific set of behavioral changes in social behavior, cognitive function, and activity; whereas quercetin shows an antidepressant-like and antioxidant effects in bulbectomized mice model via the glutamatergic and oxidonitrergic pathways, and mediate neuroinflammatory-apoptotic cascade response.
Furthermore, quercetin acts as an antidepressant by targeting SIRT1 to reverse depressive and anxiety-like behaviors and hippocampal neuroinflammation. The FoxG1/CREB/BDNF/Trkβ-catenin axis clarify the underlying mechanisms (Figure 5 and Table 4).
3 Effects of quercetin on osteoporosis
Osteoporosis is also a major aging-related disease. The rate of reduction of osteogenic differentiation and bone formation is the major cause of aging-related osteoporosis. Bone can act indirectly on the brainstem, midbrain and hippocampus, thereby affect the synthesis of multiple neurotransmitters, resulting in neurodegenerative diseases, suggesting that improving the conditions affecting neurodegenerative process may be a novel target for the treatment of bone injury. Osteoporosis is characterized by a reduction in the bone mass and bone mineral loss, and deterioration of bone microarchitecture, with a greater impact on postmenopausal women. In the United States, approximately 53 million people are at risk of bone mineral loss, however, this number will gradually increase resulting in an economic loss of an annual cost of $25.3 billion.
Quercetin is a potential drug for the clinical treatment of osteoporosis and has a significant effect on the structure and conformation of bone morphogenetic protein-2 (BMP-2) via upregulation of bone mineralization which promotes differentiation of bone marrow mesenchymal stem cells (BMSCs), as well as osteoblast-specific genes such as osterix (OSX), dwarf-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), osteocalcin (OCN), and serum c-terminal type I collagen cross-linked telopeptides at the mRNA and protein expression levels. Quercetin promotes osteogenic differentiation and inhibits lipogenic differentiation of mouse bone marrow mesenchymal stem cells (mBMSCs), enhancing AMPK protein phosphorylation and upregulating SIRT1 expression to exert antioxidant effects. Thereby promoting bone marrow mesenchymal stem cell proliferation and osteogenic differentiation. Rodent oophorectomy is extensively studied for to determine a reduction in bone mass and an increase in bone turnover in cancellous bone, which is similar to osteoporosis in postmenopausal women.
The activation of nicotine and muscarinic receptors (nAchR) in an osteoclast inhibits the receptor activator of nuclear factor-kappa B ligand (RANKL)-dependent osteoclast development, suggesting that it is closely related to sympathetic nerve activity. Quercetin has been shown to inhibit RANKL-mediated osteoclastogenesis, osteoblast apoptosis, and inflammatory response, nuclear factor κB (NF-κB) and activator protein 1 (AP-1) are transcription factors that regulates osteoclast differentiation, and signaling pathways associated with β-catenin degradation. Quercetin is inhibits osteoclast differentiation in vitro. The abundance of phosphorylated p38 MAPK and phosphorylated extracellular signal-regulated kinase (ERK) could be reverse after quercetin treatment, and trigger significant restoration of the Wnt/β-catenin pathway by enhancing the expression of Wnt3, β-catenin, Bax and cytochrome c expression and decrease the expression of Bcl-2, Bcl-xL and caspase-3, regulating autophagy and apoptosis to prevent osteoporosis.
In summary, quercetin acts as a therapeutic measure for treating aging-related osteoporosis by targeting SIRT1, via antioxidants pathways, thereby inhibits osteoblast apoptosis, autophagy, and inflammatory responses (Figure 6 and Table 5).
4.1 Myocardial ischemia (M/I) and reperfusion (MI/R)
Myocardial ischemia is an aging-related cardiovascular disease and causes sudden death worldwide. Myocardial ischemia (M/I) infarction is caused by an inadequate supply of oxygen to the heart, leading to apoptosis. However, cardiomyocytes damage is caused by calcium overload, large amounts of free radical production, and infiltration of inflammatory cells cause reperfusion. Mitochondrial dysfunction is considered an important marker of neuronal death during cerebral MI/R.
The cardioprotective effect of quercetin is associated with attenuating oxidative stress induced by aging. In a mice model, quercetin was reported to attenuate cardiac damage induced by a high-fat diet (HFD) by restoring myocardial microcirculation, reducing infarct size and improving left ventricular function, myofibrillar and mitochondrial structure. Quercetin also improve the tricarboxylic acid cycle and respiratory chain-related enzyme activity in rats with myocardial infarction, as well as decrease the expression of biomarkers of myocardial induced oxidative stress in rats with myocardial infarction. In addition, quercetin protects AC16 cells from HG-induced oxidative stress by elevating p-SIRT1, endothelial NOS, and decreasing iNOS through the PI3K/Akt/Nrf2 signaling pathway.
Pretreatment with quercetin significantly inhibit inflammatory cascade responses through the downregulation of HMGB1-TLR4-NF-κB signaling pathway. Quercetin protects against myocardial apoptosis in vivo via phosphorylation of JNK and p38, increasing Bcl-2 expression and directly or indirectly inhibiting the activation of Bax and caspase 3, as well as ameliorates MI/R-induced apoptosis through SIRT1/PGC-1α signaling.
Evidence shows that sympathetic excitatory reflexes exacerbate myocardial injury. In a neuropathic pain model a central mechanism through the inhibition of mitochondrial permeability transition pore (mPTP) opening or involving the activation of paraventricular thalamic (PVA) neurons induce cardioprotective effects.
Therefore, quercetin could be used as a potential therapeutic drug for reducing MI/R injury via SIRT1/PI3K/Akt/Nrf2 mediated oxidative stress, SIRT1/PGC1α and HMGB1/TLR4/NF-κB mediated inflammatory response, and SIRT1/p38 MAPK mediated apoptosis pathways (Figure 7 and Table 6).
4.2 Atherosclerosis (AS)
Atherosclerosis promotes mortality and morbidity in aging-related cardiovascular diseased models. Endothelial dysfunction is an important process involved in atherosclerosis. A solute exchange between the blood and nerve tissues have a direct contact and are intact by the blood-nerve barrier (BNB), consisting of the endothelium surrounding peripheral nerve substructures. Oxidized low-density lipoprotein (ox-LDL)-induced oxidative damage to endothelial cells cause atherosclerosis. Thus, oxLDL-induces the formation of RAW264.7 macrophage-derived foam cells that exacerbate cellular lipid accumulation, and elevate the levels of ROS that lead to oxidation of LDL particles to produce ox-LDL, whereas quercetin inhibits cholesterol accumulation-induced apoptosis of macrophages, thereby reducing atherosclerosis. In addition, quercetin enhances cellular antioxidant function through the Nrf2 pathway. Further studies have showed that quercetin inhibits ox-LDL induced oxidative damage in AS via activating SIRT1 and modulating the AMPK/NADPH/AKT signaling pathway, as well as inhibits inflammatory/oxidative stress responses in AS via AMPK/SIRT1/NF-κB pathway, and attenuated AS by increasing the density of SIRT1. Another reports in mice have indicated that quercetin attenuates high fat diet-induced atherosclerosis in apolipoprotein E knockout mice by alleviating systemic oxidative stress and also inhibit aortic P47phox by blocking the activation of NADPH oxidase-P47phox membrane translocation.
During aging, chronic atherosclerosis promotes ROS production and accumulation which eventually cause mitochondria damage, due to mtDNA damage. OxLDL molecules are immunogenic and are associated with innate immunity to pattern recognition receptors, including scavenger receptors and TLR, and NF-κB, whereas quercetin significantly inhibit NLRP3 inflammatory vesicle activation in the ox-LDL-containing macrophages, thereby attenuating cell lipoatrophy and IL-1β secretion. Ex vivo studies have reported that quercetin (25 μM) reduce the HUVEC expression of VCAM-1, where ICAM-1 was significantly enhanced, and then attenuate oxLDL induced endothelial leukocyte adhesion, and effectively modulate the TLR-NF-κB signaling pathway by attenuating the inflammatory process in atherosclerosis. Quercetin inhibits the formation of atherosclerotic plaque, and the main mechanism of action is related to the PI3K/AKT-related regulation of caspase-3 and NF-κB activation. Moreover, quercetin decrease the mRNA expression of TNF-α and TLR4 in atherosclerotic rats, and the mechanism of action is related to the TLR4-mediated MAPK pathway by reducing the levels of expression of pro-inflammatory cytokines (IL-1β, TNF-α, and IL-10). Dysregulation of TLRs has been reported to increase inflammation and metabolic syndrome which cause the development and progression of atherosclerosis.
Therefore, quercetin play an important role in the treatment of atherosclerosis by preventing endothelial cell damage via SIRT1/AMPK/Nrf2 mediated oxidative stress, SIRT1/PI3K/Akt/NF-κB and SIRT1/TLRs/MAPK mediated inflammatory response (Figure 8 and Table 7).
5 Effects of quercetin on diabetes
Diabetes is a metabolic disorder that cause death in human populace worldwide (mostly in elderly people). The International Diabetes Federation reported that people suffering from diabetes equally exhibit neuropathy and neuropathic pain. The most common manifestation of diabetic neuropathy is distal symmetric polyneuropathy (DSPN), which affects approximately 30% of diabetic patients with the most relevant clinical manifestations, whereas the incidence of DSPN is approximately 2% per year. However, the pathogenesis is unclear, and clinical and epidemiological studies have indicated that oxidative stress and inflammatory processes are important pathological mechanisms in diabetic neuropathy, which is associated with distal symmetric sensorimotor polyneuropathy.
ROS is associated with the development of neuropathy in an experimental diabetes. The findings in streptozotocin (STZ)-injected diabetic rats suggest that oxidative stress cause neurotransmission defects. Quercetin has been shown to have a beneficial effect on nicotinamide/streptozotocin-induced antidiabetic and antioxidant capacity in Wistar diabetic rats, reducing dorsal root ganglion (DRG) neurons damage by oxidative stress. Overproduction and accumulation of ROS and reactive carbonyl compounds induces endoplasmic reticulum stress (ERs). Quercetin was found to induce lysosomal defects which triggered ERs and ROS generation, thereby contributing to glioma cell death. Quercetin can bypass the GLUT4 translocation insulin regulatory system through the AMPK signaling pathway and its downstream target p38 MAPK, thereby contributing to the correction of insulin resistance.An increase AMPK, insulin receptor substrate 1 (IRS-1) and AS160 phosphorylation increase GSK3β under insulin-stimulated conditions. Quercetin induces insulin secretion by direct activation of L-type calcium channels in pancreatic beta cells, thus, quercetin interacts with L-type Ca2+ channels at a location different from that of Bay K 8644 to increase Ca2+ influx, which stimulates insulin secretion and thus, reduce the insulin levels. Quercetin improves endothelial function by inhibiting endoplasmic reticulum stress-mediated disruptions leading to the degeneration of islet initiation of the UPR response, and calcium homeostasis, thereby reducing oxidative stress in diabetic rats.
SOD is the main antioxidant parameter which prevents neuronal damage. Quercetin enhance the expression of antioxidant indices, thereby protects the mitochondrial function by increasing intracellular nicotinamide-adenine dinucleotide (NAD+) and may be involved in regulating NF-κB and SIRT1 levels. Further mechanisms may be related to the upregulation of SIRT1 activity and protein levels, and its effects on the Akt signaling pathway. In diabetic neuropathy, axonal and sensory neuron degeneration pathways are activated, leading to distal axonal lesions. The NAD+-dependent deacetylase SIRT1 prevents the activation of these pathways and promotes axonal regeneration.
Recent studies have demonstrated that ferroptosis, a newly identified form of regulated cell death characterized by iron-dependent dependence on the overproduction of ROS leading to irreparable lipid peroxidation, is involved in β-cell death leading to reduced insulin secretion. The protective effect of quercetin on mice pancreas occurs partly through the inhibition of hypertrophy.
In general, the application of quercetin at the appropriate dose could serve as a potential therapeutic agent in treating diabetes, by attenuating oxidative stress and ferroptosis (Figure 9 and Table 8).
6 Discussion
Aging is an irreversible physiological process, and the incidence of neurological diseases increases with age. Neurodegenerative diseases have been recognized as a manifestation of chronological aging. Therefore, it is important to identify suitable anti-aging drugs and explore their therapeutic mechanisms. Oxidative stress, neuroinflammation, apoptosis, autophagy, and mitochondrial dysfunction are significant causative factors related to aging-related diseases. Recently, numerous studies have reported the protective effects of SIRT1 in aging-related diseases, such as protective effect against neurodegeneration, regulation of oxidative stress, inflammatory response, mitochondrial biogenesis, cell death, and autophagy. Quercetin is an anti-aging flavonoid, because it possesses antioxidant, anti-apoptotic, anti-inflammatory properties, as well as can actively participate in the improvement of mitochondrial dysfunctions, thereby could be used as a novel therapeutic measure in treating aging-related diseases. Therefore, recently researchers focus on investigating the medicinal effects of quercetin and its mechanism in attenuating aging-related diseases.
Several studies have shown that quercetin protects against neurodegenerative diseases by enhancing the mechanism of SIRT1 deacetylase. However, low bioavailability and solubility of quercetin limits its clinical application. In addition, most of the current studies only focused on quercetin glycosides, however, the functions of the gut micobiota helps to breakdown quercetin into serious biological metabolites such as phloroglucinol, 3,4-dihydroxyphenylacetic acid, 4-hydroxyphenylacetic acid, and 3,4-dihydroxybenzaldehyde. Therefore, it is important to examine the potential therapeutic effects of these intestinal metabolites obtained from quercetin.
6.1 Quercetin regulates oxidative stress via SIRT1
Oxidative stress, mitochondrial dysfunction, inflammatory, and cell autophagy and apoptosis are pathophysiological factors responsible for initiating aging-related diseases. There is a correlation between oxidative stress and aging. Thus, with chronological aging, ROS production and accumulation from multiple sources increases, whereas the levels of antioxidant enzymes and repair systems (proteasomal degradation) decline. Reports have shown that quercetin improve the concentration antioxidant enzymes and anti-inflammatory cytokines, as well as improve mitochondrial function by targeting SIRT1 activity via the SIRT1/AMPK/NF-κB, SIRT1/Keap1/Nrf2/HO-1, and SIRT1/PI3K/Akt pathways.
In a rat model, it was indicated that quercetin inhibited ER stress to attenuate oxidative stress-induced apoptosis and prevent the progression of osteoarthritis by activating the SIRT1/AMPK pathway in rat chondrocytes, and inhibited oxidative stress responses in diabetic high fat diet-induced atherosclerosis in the carotid artery of rats by modulating AMPK/SIRT1/NF-κB pathway. Quercetin inhibited oxidative stress to ameliorate diabetic encephalopathy via SIRT1/ER stress pathway in db/db mice, furthermore, it inhibited oxidative stress damage to regulate mitophagy and ER stress via SIRT1/TMBIM6 (transmembrane BAX inhibitor-1 motif-containing 6) in cardiovascular diseases, as well as attenuated collagen-induced oxidative stress in mice arthritis by mediating SIRT1 activation. Moreover, Quercetin was found to reduce oxLDL-induced oxidative damage by upregulating AMPK and SIRT1 activity; and reduce oxidative damage in the liver and kidney tissues, and NF-kB levels by increasing SIRT1 in diabetes model.
6.2 Quercetin regulates inflammatory response via SIRT1
The attenuation of the inflammatory response is a potential anti-aging strategy. Senescent cell expression is the most pronounced in post-mitotic cells, whereas mitochondria and lysosomes suffer the most significant aging-related alterations in all organelles. Studies have confirmed that SIRT1 activation can inhibit NF-κB, TLRs, and NLRP3 pathways to reduce inflammation. Activation of these SIRT1-dependent signaling pathways by quercetin result in the modulation of the levels and functions of the inflammatory cytokines. Quercetin modulates AMPK/SIRT1/NF-κB pathway to inhibit inflammatory responses in diabetic high fat diet-induced atherosclerosis in the carotid artery of rats. In addition, quercetin alleviates inflammatory responses by activating SIRT1 and inhibit NF-κB pathway, furthermore, it contributes to anti-inflammatory effect by modulating SIRT1 activation via AMPK/SIRT1/Nfr2/TNFα pathway, as well as counteracts cholesterol-induced activation of the NF-κB pathway in the pancreas and normalized the expression of pro-inflammatory cytokines by increasing SIRTI expression, and reduce inflammation response in obesity mice through AMPKα1/SIRT1 pathway.
6.3 Quercetin regulates mitochondrial function via SIRT1
Mitochondrial dysfunction contributes significantly to aging-related diseases. However, treatment with quercetin could reduce ROS generation and mitigate mitochondrial dysfunction, thereby maintaining the mitochondrial homeostasis and normal function. Quercetin suppressed oxLDL-induced mitochondrial dysfunction and ROS formation by activating SIRT1 and modulating the AMPK/NADPH/AKT pathway, and attenuate mitochondrial dysfunction via activating AMPK/SIRT1 pathway in osteoarthritis rats. Moreover, quercetin mitigate cerebral ischemia reperfusion injury and reduce ROS generation in the mitochondria via SIRT1/Nrf2/HO-1 pathway.
Quercetin, as SIRT1 agonists, promotes mitochondrial biogenesis thereby attenuates mitochondrial diseases, prevented cholesterol-induced mitochondrial bioenergetic dysfunction by upregulating the expression of SIRT1 in the Min6 cells, and promotes mitochondrial biogenesis in the brain by activating the transcription of SIRT1. Quercetin as SIRT1/PGC1-α activator was reported to improved cardiac function in aged Mdx/Utrn+/- mice by increasing the protein contents and decrease inflammatory markers NF-κB in the mitochondria.
6.4 Quercetin regulates autophagy and apoptosis via SIRT1
During the occurrence of aging-related diseases, cell become vulnerable to the accumulation of abnormal proteins and damage to the phagocytic lysosomal system, which eventually cause cell death. Quercetin-induced autophagy contributes to apoptosis via SIRT1/AMPK pathway in lung cancer cells, moreover, quercetin inhibits apoptosis and attenuates intervertebral disc degeneration by promoting SIRT1-dependent autophagy, as well as improve MI/R-induced cardiomyocyte apoptosis via SIRT1/PGC-1α pathway, and regulate autophagy and mitochondrial ROS homeostasis via Nrf2/PGC-1α/SIRT1 pathway in sodium iodate-induced retinal damage. A study identify that quercetin could rescue cardiomyocyte hypoxia by regulating SIRT1/TMBIM6-related mitophagy, and reduce renal tubular epithelial cell senescence by activating SIRT1/PINK1/Parkin-mediated mitophagy. In addition, other studies have showed that quercetin exerts protective effects against cholesterol-induced apoptosis by improving the expression of SIRTI and inhibits cytochrome c release in Min6 cells.
7 Conclusions and future perspectives
The pharmacological efficacy of quercetin has shown that it possesses promising therapeutic potentials. In this review, we highlighted the role of quercetin in targeting SIRT1 with the aim of preventing aging-related diseases via oxidative stress and inflammation alleviation, as well as the restoration of mitochondrial dysfunction. Therefore, SIRT1 may serve as a potential therapeutic target for the treatment of aging-related diseases.
Recent studies on aging-related diseases have indicated that ferroptosis contributes in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Depression, Osteoarthritis, Myocardial ischemia and reperfusion (MI/R), Atherosclerosis, and Diabetes. Notably, quercetin shows iron-chelating activity and effectively decrease iron deposition in the hearts, kidneys and liver of iron-dextran-overloaded mice, and protects bone marrow-derived mesenchymal stem cells from erastin-induced ferroptosis through antioxidant pathway. Therefore, quercetin was identified as a ferroptosis inhibitor to alleviate acute kidney injury. Moreover, activation of SIRT1 inhibits excess iron-induced ferroptosis of foam cells, thereby providing a novel therapeutic target for atherosclerosis, and fisetin attenuated doxorubicin-induced cardiomyopathy by inhibiting ferroptosis via the activation of SIRT1/Nrf2 signaling pathway. Thus, acting as an intracellular iron chelators, as well as stimulating cellular degradation systems provide novel mechanisms for aging research and may be potential diagnostic biomarkers for aging-related disease in the future. The future challenge is to establish models of ferroptosis on disease-specific basis so that the underlying mechanisms of action can be investigated in detail.
Recently, various studies have suggested that extracellular vesicles (EVs) have multiple advantages over currently available drug delivery vehicles, opening new frontiers for modern drug delivery. Therefore, EVs can be considered for quercetin loading and delivery for treating aging-related disease. In addition, EVs can successfully communicate between cells and organs in the aging microenvironment and during the occurrence of aging-related diseases. In particular, neuron-derived EVs can breach the blood-brain barrier (BBB) and become important carriers of signals between cell types in the central nervous system (CNS).
Recent studies have shown that EVs can reduce glutamate expression in the neurons to improve cognitive function and reduce Aβ plaques in AD model mice by activating the SIRT1 pathway. The loss of SIRT1 support could accelerated EV production, which carry pathological α-SYN and preferentially target microglia to induce microglial inflammation. The release of circulating EVs with oxidative contents alters redox and mitochondrial homeostasis in the brains of rats, suggesting that SIRT1-mediated EVs obtained from different donors may also be promising materials and tools for anti-aging disease therapy.
In this comprehensive review, we have found clues from separate studies and found that quercetin could regulate oxidative stress, inflammatory response, mitochondrial dysfunction, autophagy and apoptosis by activating SIRT1 in aging-related disease. However, there are limited in vivo clinical studies on this subject matter, due to limitations such as low bioavailability and solubility of quercetin and disease complexity, therefore, several clinical in vivo studies should be carried out to explore the pharmacological effects and the pharmacokinetics of metabolites to establish and identify useful clinical metabolites released from quercetin catabolism by the gut microbiota. Moreover, whether EVs could be considered for quercetin loading and delivery for treating aging-related disease, and whether quercetin could alleviate ferroptosis to protect against aging-related disease by activating SIRT1 requires further studies.
Author contributions
Conceptualization, ZC and XZ (2nd author); Literature review, YW, GS, YT, XD, and DL; Writing – original draft, ZC and XZ (2nd author); Writing – review & editing, ZC, FA, and XZ (2nd author). All authors have read and agreed to the published version of the manuscript.
Funding
This study was financially funded by Sichuan Science and Technology Program (2020JDRC0104), the Key Research & Development Plan of the Department of Science and Technology of Tibet Autonomous Region (XZ202101ZY0002N), the Local Projects Guided by the Central Government from Razi County, Tibet Autonomous Region, and the Projects Funded by the Central Government to Guide Local Scientific and Technological Development from Guizhou province (QIANKEZHONGYINDI[2021]4003).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References 259
- 1.
Zhang W Qu J Liu GH Belmonte JCI. The ageing epigenome and its rejuvenation. Nat Rev Mol Cell Biol (2020 ) 21(3):137–50
Not in our library10.1038/s41580-019-0204-5
- 2.
Kalaria RN Maestre GE Arizaga R Friedland RP Galasko D Hall K. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol (2008 ) 7(9):812–26
Not in our library10.1016/s1474-4422(08)70169-8
- 3.
Zhang M Bian Z. The emerging role of circular rnas in alzheimer's disease and parkinson's disease. Front Aging Neurosci (2021 ) 13:691512
Not in our library10.3389/fnagi.2021.691512
- 4.
Šonský I Vodička P Vodičková Kepková K Hansíková H. Mitophagy in huntington's disease. Neurochem Int (2021 ) 149:105147
Not in our library10.1016/j.neuint.2021.105147
- 5.
Terao T. Neglected but not negligible aspects of antidepressants and their availability in bipolar depression. Brain Behav (2021 ) 11(8):e2308
Not in our library10.1002/brb3.2308
- 6.
Kalinkovich A Livshits G. Biased and allosteric modulation of bone cell-expressing g protein-coupled receptors as a novel approach to osteoporosis therapy. Pharmacol Res (2021 ) 171:105794
Not in our library10.1016/j.phrs.2021.105794
- 7.
Chouchani ET Pell VR Gaude E Aksentijević D Sundier SY Robb EL. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ros. Nature (2014 ) 515(7527):431–5
Not in our library10.1038/nature13909
- 8.
Gueguen N Lenaers G Reynier P Weissig V Edeas M. Mitochondrial dysfunction in mitochondrial medicine: current limitations, pitfalls, and tomorrow. Methods Mol Biol (Clifton NJ) (2021 ) 2276:1–29
Not in our library10.1007/978-1-0716-1266-8_1
- 9.
Cuadros DF Li J Musuka G Awad SF. Spatial epidemiology of diabetes: methods and insights. World J Diabetes (2021 ) 12(7):1042–56
Not in our library10.4239/wjd.v12.i7.1042
- 10.
Hou Y Dan X Babbar M Wei Y Hasselbalch SG Croteau DL. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol (2019 ) 15(10):565–81
Not in our library10.1038/s41582-019-0244-7
- 11.
López-Otín C Blasco MA Partridge L Serrano M Kroemer G. The hallmarks of aging. Cell (2013 ) 153(6):1194–217
Not in our library10.1016/j.cell.2013.05.039
- 12.
Emmerzaal TL Nijkamp G Veldic M Rahman S Andreazza AC Morava E. Effect of neuropsychiatric medications on mitochondrial function: for better or for worse. Neurosci Biobehav R (2021 ) 127:555–71
Not in our library10.1016/j.neubiorev.2021.05.001
- 13.
Ferrucci L Fabbri E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat Rev Cardiol (2018 ) 15(9):505–22
Not in our library10.1038/s41569-018-0064-2
- 14.
Mulica P Grünewald A Pereira SL. Astrocyte-neuron metabolic crosstalk in neurodegeneration: a mitochondrial perspective. Front Endocrinol (2021 ) 12:668517
Not in our library10.3389/fendo.2021.668517
- 15.
Singh V Ubaid S. Role of silent information regulator 1 (sirt1) in regulating oxidative stress and inflammation. Inflammation (2020 ) 43(5):1589–98
Not in our library10.1007/s10753-020-01242-9
- 16.
Seto E Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. CSH Perspect Biol (2014 ) 6(4):a018713
Not in our library10.1101/cshperspect.a018713
- 17.
Osborne B Bentley NL Montgomery MK Turner N. The role of mitochondrial sirtuins in health and disease. Free Radical Bio Med (2016 ) 100:164–74
Not in our library10.1016/j.freeradbiomed.2016.04.197
- 18.
Shahgaldi S Kahmini FR. A comprehensive review of sirtuins: with a major focus on redox homeostasis and metabolism. Life Sci (2021 ) 282:119803
Not in our library10.1016/j.lfs.2021.119803
- 19.
Fang Y Wang X Yang D Lu Y Wei G Yu W. Relieving cellular energy stress in aging, neurodegenerative, and metabolic diseases, sirt1 as a therapeutic and promising node. Front Aging Neurosci (2021 ) 13:738686
Not in our library10.3389/fnagi.2021.738686
- 20.
Bai L Liu R Wang R Xin Y Wu Z Ba Y. Attenuation of pb-induced aβ generation and autophagic dysfunction via activation of sirt1: neuroprotective properties of resveratrol. Ecotox Environ Safe (2021 ) 222:112511
Not in our library10.1016/j.ecoenv.2021.112511
- 21.
- 22.
- 23.
Tripodi F Lombardi L Guzzetti L Panzeri D Milanesi R Leri M. Protective effect of vigna unguiculata extract against aging and neurodegeneration. Aging (2020 ) 12(19):19785–808
Not in our library10.18632/aging.104069
- 24.
Finkel T Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature (2000 ) 408(6809):239–47
Not in our library10.1038/35041687
- 25.
Teng WL Huang PH Wang HC Tseng CH Yen FL. Pterostilbene attenuates particulate matter-induced oxidative stress, inflammation and aging in keratinocytes. Antioxidants (Basel Switzerland) (2021 ) 10(10):1552
Not in our library10.3390/antiox10101552
- 26.
Fontana L Ghezzi L Cross AH Piccio L. Effects of dietary restriction on neuroinflammation in neurodegenerative diseases. J Exp Med (2021 ) 218(2):e20190086
Not in our library10.1084/jem.20190086
- 27.
- 28.
Zhao X Wang J Deng Y Liao L Zhou M Peng C. Quercetin as a protective agent for liver diseases: a comprehensive descriptive review of the molecular mechanism. Phytother Res (2021 ) 35(9):4727–47
Not in our library10.1002/ptr.7104
- 29.
Grewal AK Singh TG Sharma D Sharma V Singh M Rahman MH. Mechanistic insights and perspectives involved in neuroprotective action of quercetin. BioMed Pharmacother (2021 ) 140:111729
Not in our library10.1016/j.biopha.2021.111729
- 30.
Luca SV Macovei I Bujor A Miron A Skalicka-Woźniak K Aprotosoaie AC. Bioactivity of dietary polyphenols: the role of metabolites. Crit Rev Food Sci Nutr (2020 ) 60(4):626–59
Not in our library10.1080/10408398.2018.1546669
- 31.
- 32.
Fasolo D Schwingel L Holzschuh M Bassani V Teixeira H. Validation of an isocratic lc method for determination of quercetin and methylquercetin in topical nanoemulsions. J Pharm BioMed Anal (2007 ) 44(5):1174–7
Not in our library10.1016/j.jpba.2007.04.026
- 33.
Rodríguez-Félix F Del-Toro-Sánchez CL Javier Cinco-Moroyoqui F Juárez J Ruiz-Cruz S López-Ahumada GA. Preparation and characterization of quercetin-loaded zein nanoparticles by electrospraying and study of in vitro bioavailability. J Food Sci (2019 ) 84(10):2883–97
Not in our library10.1111/1750-3841.14803
- 34.
Lee YJ Park Y. Green synthetic nanoarchitectonics of gold and silver nanoparticles prepared using quercetin and their cytotoxicity and catalytic applications. J Nanosci Nanotechnol (2020 ) 20(5):2781–90
Not in our library10.1166/jnn.2020.17453
- 35.
- 36.
Tang SM Deng XT Zhou J Li QP Ge XX Miao L. Pharmacological basis and new insights of quercetin action in respect to its anti-cancer effects. BioMed Pharmacother (2020 ) 121:109604
Not in our library10.1016/j.biopha.2019.109604
- 37.
Hu Y Gui Z Zhou Y Xia L Lin K Xu Y. Quercetin alleviates rat osteoarthritis by inhibiting inflammation and apoptosis of chondrocytes, modulating synovial macrophages polarization to m2 macrophages. Free Radical Bio Med (2019 ) 145:146–60
Not in our library10.1016/j.freeradbiomed.2019.09.024
- 38.
Andres S Pevny S Ziegenhagen R Bakhiya N Schäfer B Hirsch-Ernst KI. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res (2018 ) 62(1):1700447
Not in our library10.1002/mnfr.201700447
- 39.
Han X Xu T Fang Q Zhang H Yue L Hu G. Quercetin hinders microglial activation to alleviate neurotoxicity via the interplay between Nlrp3 inflammasome and mitophagy. Redox Biol (2021 ) 44:102010
Not in our library10.1016/j.redox.2021.102010
- 40.
Huang YY Wang ZH Deng LH Wang H Zheng Q. Oral administration of quercetin or its derivatives inhibit bone loss in animal model of osteoporosis. Oxid Med Cell Longev (2020 ) 2020:6080597
Not in our library10.1155/2020/6080597
Cited by papers we hold 6
- Endothelial dysfunction: molecular mechanisms and clinical implications · 2024No notice
- Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction · 2024No notice
- The Potential Benefits of Quercetin for Brain Health: A Review of Anti-Inflammatory and Neuroprotective Mechanisms · 2023No notice
- Novel Role of the SIRT1 in Endocrine and Metabolic Diseases · 2023No notice
- Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants · 2023No notice
- Possible Mechanisms of Oxidative Stress-Induced Skin Cellular Senescence, Inflammation, and Cancer and the Therapeutic Potential of Plant Polyphenols · 2023No notice
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.